(Q35106858)

6 August 2017

0 references

1 reference

title

Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis (English)

1 reference

6 August 2017

Comparative effectiveness of full‐length and B‐domain deleted factor VIII for prophylaxis – a meta‐analysis (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

24 December 2023

1 reference

R. A. Gruppo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694514

24 December 2023

D. Brown

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694514

24 December 2023

M. M. Wilkes

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694514

24 December 2023

R. J. Navickis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694514

24 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12694514

24 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2516.2003.00769.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2516.2003.00769.x

24 December 2023

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

24 December 2023

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

251-260

1 reference

The impact of prophyactic treatment on children with severe haemophilia

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Haemophilia prophylaxis in young patients--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Bias in location and selection of studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

A meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Prophylactic treatment in Sweden--overtreatment or optimal model?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Experience of prophylaxis treatment in children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Comparative study of four different pharmacokinetic computer programs: case study of a factor VIII preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Influence of phospholipids on the assessment of factor VIII activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

Analysis of samples from patients treated with ReFacto for the presence of anti-SQ-peptide specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00769.X

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Aspects of haemophilia prophylaxis in Sweden

24 December 2023

9

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity

24 December 2023

12

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients

24 December 2023

14

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients

24 December 2023

15

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Should unpublished data be included in meta-analyses? Current convictions and controversies

24 December 2023

20

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Meta-analysis of published data using a linear mixed-effects model

24 December 2023

21

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

24 December 2023

23

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis

24 December 2023

28

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

24 December 2023

37

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies.

24 December 2023

38

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.

24 December 2023

41

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A

24 December 2023

49

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

In Vivo Recovery and Survival of Monoclonal-Antibody-Purified Factor VIII Concentrates

24 December 2023

51

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates

24 December 2023

52

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies

24 December 2023

53

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels

24 December 2023

55

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients

24 December 2023

69

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule

24 December 2023

76

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII

24 December 2023

77

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization

24 December 2023

81

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

Structural and functional characterization of B-domain deleted recombinant factor VIII.

24 December 2023

82

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00769.X

24 December 2023

Identifiers

1 reference

6 August 2017

1 reference